Dr. Tony Sedgwick, Chief Executive Officer of Novacta said: "We have worked closely with CP2 to consummate this investment, one of the largest in Europe this year. We have made great progress with our technology platform and pipeline and now have the funds to accelerate development. In particular, access to the expertise at CP2 will ensure that we develop drugs to the standards looked for by big pharma and maximise their commercial value. I would like to thank Andy Sandham for his leadership and wise counsel as our outgoing Chairman and welcome Andy Richards to the role. We are also pleased that Richard and Bob are joining the Board from CP2."
Notes to Editors
About Celtic Pharma Holdings Advisors LLP
Celtic Pharma Holdings Advisors is a global private equity fund management partnership focused on the biotechnology and pharmaceutical industries. Our second fund, Celtic Pharma Holdings II LP, invests in companies which own proven technology platforms and early clinical development-stage pharmaceutical programmes and directs the management of these programmes through their development prior to sale at proof of concept with appropriate efficacy and safety data (usually at end of Phase II clinical trials).
CP2 has already attracted investment from sovereign wealth funds, pension funds and high net worth individuals from many countries and continues to raise further capital. For further information, please visit our website at www.celticpharmaholdings.com.
About Novacta Biosystems Limited
Novacta is a UK-based biotechnology company that specialises in the
discovery and development of potential treatments for infectious diseases.
Novacta's lead programmes are cent
|SOURCE Celtic Pharma Holdings Advisors LLP|
Copyright©2009 PR Newswire.
All rights reserved